Oncology Trends and Testing Gaps Shape Precision Care Delivery: Abby Kim, PharmD

Why It Matters

Closing testing gaps speeds appropriate treatment, boosting patient outcomes and reducing costly delays. Standardized guidelines and pathway reforms help payers and providers curb wasteful oncology spending.

Key Takeaways

• Six oncology trends identified to guide precision care strategies
• Biomarker testing gaps delay access to effective novel therapies
• AMCP aims to standardize guideline language for testing timing
• Education push targets providers on cancer biomarker testing requirements
• Clinical pathways now prioritize avoiding low‑value oncology drugs

Pulse Analysis

The oncology landscape is undergoing rapid transformation as targeted therapies and immunotherapies move from clinical trials to mainstream practice. These advances promise higher response rates and longer survival, but they also demand precise molecular profiling to match the right drug to the right patient. As a result, clinicians are increasingly reliant on biomarker tests—ranging from next‑generation sequencing panels to companion diagnostics—to inform treatment decisions and justify reimbursement.

Despite the clinical benefits, a persistent testing gap hampers the full realization of precision oncology. Patients often experience delays because providers lack clear guidance on which cancers require testing, when to order assays, or how to interpret results. Recognizing this, the Academy of Managed Care Pharmacy is spearheading two key initiatives: harmonizing the language in national guidelines to distinguish mandatory from optional testing, and rolling out a broad education campaign aimed at both managed‑care pharmacists and frontline oncologists. By clarifying expectations and improving test utilization, AMCP hopes to shorten time‑to‑therapy and reduce unnecessary diagnostic repeats.

Concurrently, the evolution of clinical pathways is shifting the focus from simply selecting effective drugs to actively excluding low‑value options. Payers are integrating value‑based criteria that consider not only efficacy but also cost, safety, and real‑world outcomes. This approach encourages the use of high‑impact therapies while discouraging adoption of expensive agents with marginal benefit. As pathways become more sophisticated, they will play a pivotal role in aligning incentives across the oncology ecosystem, ensuring that innovative treatments reach patients who stand to gain the most while preserving the sustainability of the healthcare system.